



MEDIGARD LIMITED
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia
Telephone +61 7 5578 7822; Fax +61 7 5528 4459
E-mail: office@medigard.com.au www.medigard.com.au
ABN 49 090 003 044

23 November 2017

ASX ANNOUNCEMENT

Medigard Ltd (“the Company”) is pleased to announce that it has received binding commitments to raise a further \$150,000 through a private placement to a sophisticated investor, directors and the company secretary.

Placement details

The placement involves the issue of 8,571,428 fully paid ordinary shares at \$0.0175 per share. The new shares will rank equally with existing shares. The shares are expected to be issued without a prospectus, from the Company’s existing capacity under Listing Rule 7.1 in the case of the 4,285,714 shares to be issued to two unrelated sophisticated investors.

Proposed issue of shares to related parties

Included in the placement commitments above are binding commitments to the Company from two of the Company’s directors:

- Dr Ian Dixon has committed to subscribe for 1,428,571 fully paid ordinary shares in the Company at an issue price of \$0.0175 per share. These shares will only be issued following the approval of shareholders.
- Mrs Patricia Boero has committed to subscribe for 1,428,571 fully paid ordinary shares in the Company at an issue price of \$0.0175c per share. These shares will only be issued following the approval of shareholders.
- Dr Chris Bishop has committed to subscribe for a further 1,428,571 fully paid ordinary shares in the company at an issue price of \$0.0175c per share. These shares will only be issued following the approval of shareholders.

A notice of meeting seeking the required approvals will be prepared and will be released to ASX when it is sent to shareholders. It is not possible to include these resolutions in the AGM due to the requirement to hold the AGM by the end of November and the notice period required.

Use of funds

Funds raised from the placement will be applied to the Company's working capital.

On receipt of the committed funds, the Company will have raised a total of \$300,000 in the recent months (subject to shareholder approval) and expects that near-term objectives can be met with this level of additional working capital.

The Company will release an Appendix 3B to ASX when each issue of shares is made.

PATRICIA BOERO
(Company Secretary)